Oxaliplatin
Oxaliplatin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Pancreatic Cancer、Metastatic Pancreatic Cancer、Metastatic Pancreatic Adenocarcinoma、Colon Adenocarcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
2 项
已进入 III/IV 期
12 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Astellas Pharma Global Development, Inc.
- Merck Sharp & Dohme LLC
- National Cancer Institute (NCI)
- Astellas Pharma Inc
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Shandong Provincial Hospital
- UNC Lineberger Comprehensive Cancer Center
- Fudan University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、Brazil、Chile、Czechia、法国、德国、意大利、日本、挪威、Singapore、South Korea
正在招募患者的 Oxaliplatin 研究
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
II 期招募中中国NCT07165847SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
II 期招募中中国NCT07284992Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
I 期 / II 期招募中美国BrazilChile中国NCT06780111Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
I 期 / II 期招募中美国NCT06483555Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
II 期招募中中国NCT06121700Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
II 期招募中中国NCT07806292Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
II 期招募中中国NCT06928584Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU
II 期招募中中国NCT07391618DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
I 期 / II 期招募中中国NCT07059650NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
II 期招募中中国NCT06405490The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
IV 期招募中中国NCT06368063AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
II 期招募中中国NCT06196697A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
I 期 / II 期招募中中国NCT06840002QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
II 期招募中中国NCT07327788Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
II 期招募中中国NCT05671822Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
III 期招募中South KoreaNCT04787354Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
II 期招募中中国NCT07315854Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
II 期招募中中国NCT07194005SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
II 期招募中中国NCT07464756Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy
II 期招募中中国NCT06586242IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
I 期 / II 期招募中中国NCT07692750sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
II 期招募中美国NCT05332002MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
II 期招募中中国NCT06840665Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer
II 期招募中中国NCT07108127
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。